论文部分内容阅读
目的:综合评价厄洛替尼用于非小细胞肺癌(non-small cell lung cancer,NSCLC)靶向治疗的国际药物经济学研究,探讨厄洛替尼的临床疗效、成本效益。方法:从MEDLINE,EMBASE等数据库检索有关表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)和治疗NSCLC的抗体类药物经济学分析的英文文献,对文献质量进行评论,系统综述靶向药物治疗NSCLC的药物经济学研究结果。结果:纳入的9篇文献显示,在一线治疗以及维持治疗中,厄洛替尼在质量调整生命年(quality-adjusted life year,QALY)无显著差异的情况下较传统化疗方案的总医疗成本更低;在二线治疗中,厄洛替尼较多西他赛在总医疗成本以及QALYs上都具备优势;在三线治疗中,厄洛替尼较最佳支持治疗效果更好,但成本也更高。结论:厄洛替尼用于NSCLC的临床一线和二线治疗更具成本效益,在维持治疗中需考虑患者的经济能力。
OBJECTIVE: To evaluate the international pharmacoeconomic study of erlotinib for the targeted therapy of non-small cell lung cancer (NSCLC) and explore the clinical efficacy and cost-effectiveness of erlotinib. METHODS: The English literature on the economics analysis of EGFR-TKI and NSCLC antibody was searched from MEDLINE, EMBASE and other databases to review the quality of the literature and to systematically review the targeted Pharmacological treatment of NSCLC in pharmacoeconomics findings. RESULTS: The nine articles included showed that erlotinib had a greater overall medical cost of more than the traditional chemotherapy regimen in first-line and maintenance therapy with no significant difference in quality-adjusted life year (QALY) Low; in second-line treatment, erlotinib more docetaxel has advantages in total medical costs and QALYs; in the third-line treatment, erlotinib better than the best supportive treatment, but the cost is higher . CONCLUSIONS: Erlotinib is more cost-effective in first-line and second-line clinical treatment of NSCLC, and the patient’s financial viability needs to be considered in maintenance therapy.